The immunoregulatory effects of total glucosides of paeony in autoimmune diseases
J Leukoc Biol. 2024 Apr 16:qiae095. doi: 10.1093/jleuko/qiae095. Online ahead of print.ABSTRACTTotal glucoside of paeonia (TGP) and its main active ingredient paeoniflorin, extracted from the Chinese herb Paeonia Lactiflora Pallas, exhibit potent immunomodulatory effects. TGP has been shown to inhibit inflammatory responses and disease progression in experimental models of multiple autoimmune diseases (AIDs), including rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, psoriasis, etc. TGP shows broad immunomodulatory effects on many immune cells such as T cells, macrophages, and dendritic cells, by reg...
Source: Journal of Leukocyte Biology - April 16, 2024 Category: Hematology Authors: Mengna Zhao Na Peng Yingbo Zhou Yuan Qu Meng Cao Qinghua Zou Qinghong Yu Liwei Lu Fan Xiao Source Type: research
Multimorbidity and the Etiology of Schizophrenia
Curr Psychiatry Rep. 2024 Apr 16. doi: 10.1007/s11920-024-01500-9. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: A global study of multimorbidity in schizophrenia, especially of the association with physical conditions, might offer much needed etiological insights.RECENT FINDINGS: Our review suggests that life-style factors and medication related to schizophrenia are only part of the explanation of the increase in risk for cardiovascular, metabolic, pulmonary disorders, and some cancers. Positive associations with autoimmune disorders (with the exception of rheumatoid arthritis) and epilepsy are promising avenues of res...
Source: Epilepsy Curr - April 16, 2024 Category: Neurology Authors: A Szoke B Pignon O Godin A Ferchiou R Tamouza M Leboyer F Sch ürhoff Source Type: research
The Oral-Lung Microbiome Axis in Connective Tissue Disease-Related Interstitial Lung Disease
Semin Respir Crit Care Med. 2024 Apr 16. doi: 10.1055/s-0044-1785673. Online ahead of print.ABSTRACTConnective tissue disease-related interstitial lung disease (CTD-ILD) is a frequent and serious complication of CTD, leading to high morbidity and mortality. Unfortunately, its pathogenesis remains poorly understood; however, one intriguing contributing factor may be the microbiome of the mouth and lungs. The oral microbiome, which is a major source of the lung microbiome through recurrent microaspiration, is altered in ILD patients. Moreover, in recent years, several lines of evidence suggest that changes in the oral and lu...
Source: Respiratory Care - April 16, 2024 Category: Respiratory Medicine Authors: Kale S Bongers Angeline Massett David N O'Dwyer Source Type: research
Targeting TNF- α-induced expression of TTR and RAGE in rheumatoid arthritis: Apigenin's mediated therapeutic approach
CONCLUSION: The findings of this study suggested that TNF-α promotes the differential expression of pro-inflammatory cytokines, TTR, and RAGE via NF-kB pathways activation. Anti-inflammatory effect of apigenin impedes TNF-α mediated dysregulation or expression associated with RA pathogenesis.PMID:38626647 | DOI:10.1016/j.cyto.2024.156616 (Source: Cytokine)
Source: Cytokine - April 16, 2024 Category: Molecular Biology Authors: None Monu Prachi Agnihotri Mohd Saquib Sagarika Biswas Source Type: research
American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17 ‐18, 2022
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided a broad perspective on current clinical development challenges and potential approaches to address them. Key takeaways are summarized in this document, including issues related to innovative clinical trial designs, use of novel o...
Source: Arthritis and Rheumatology - April 16, 2024 Category: Rheumatology Authors: Jonathan Kay,
Nikolay P. Nikolov,
Michael H. Weisman,
for the
American College of Rheumatology Committee on Research Tags: Special Article Source Type: research
Multimorbidity and the Etiology of Schizophrenia
AbstractPurpose of ReviewA global study of multimorbidity in schizophrenia, especially of the association with physical conditions, might offer much needed etiological insights.Recent FindingsOur review suggests that life-style factors and medication related to schizophrenia are only part of the explanation of the increase in risk for cardiovascular, metabolic, pulmonary disorders, and some cancers. Positive associations with autoimmune disorders (with the exception of rheumatoid arthritis) and epilepsy are promising avenues of research but to date have not been fully exploited. The same holds for the negative comorbidit...
Source: Current Psychiatry Reports - April 16, 2024 Category: Psychiatry Source Type: research
The Oral –Lung Microbiome Axis in Connective Tissue Disease-Related Interstitial Lung Disease
Semin Respir Crit Care Med DOI: 10.1055/s-0044-1785673Connective tissue disease-related interstitial lung disease (CTD-ILD) is a frequent and serious complication of CTD, leading to high morbidity and mortality. Unfortunately, its pathogenesis remains poorly understood; however, one intriguing contributing factor may be the microbiome of the mouth and lungs. The oral microbiome, which is a major source of the lung microbiome through recurrent microaspiration, is altered in ILD patients. Moreover, in recent years, several lines of evidence suggest that changes in the oral and lung microbiota modulate the pulmonary immune re...
Source: Seminars in Respiratory and Critical Care Medicine - April 16, 2024 Category: Respiratory Medicine Authors: Bongers, Kale S. Massett, Angeline O'Dwyer, David N. Tags: Review Article Source Type: research
The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis
Ann Intern Med. 2024 Apr;177(4):546-547. doi: 10.7326/L24-0006.NO ABSTRACTPMID:38621267 | DOI:10.7326/L24-0006 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Andriko Palmowski Maarten Boers John Kirwan Robin Christensen Frank Buttgereit Source Type: research
The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis
Ann Intern Med. 2024 Apr;177(4):546. doi: 10.7326/L24-0005.NO ABSTRACTPMID:38621266 | DOI:10.7326/L24-0005 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Alexander Theophilopoulos Michael R Bubb Source Type: research
The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis
Ann Intern Med. 2024 Apr;177(4):545-546. doi: 10.7326/L24-0004.NO ABSTRACTPMID:38621265 | DOI:10.7326/L24-0004 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kavita Narula Katharine Lazarus Sirazum Choudhury Karim Meeran Source Type: research
The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis
Ann Intern Med. 2024 Apr;177(4):545. doi: 10.7326/L24-0003.NO ABSTRACTPMID:38621264 | DOI:10.7326/L24-0003 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Daniel Arkfeld Sofia Audrey B Gonzales Katherine Ruddy Source Type: research
Rheumatology: What You May Have Missed in 2023
Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0678. Online ahead of print.ABSTRACTMany patients with rheumatologic conditions receive care from physicians other than rheumatologists. Here we note key findings from 6 studies in rheumatology published in 2023 that offer valuable insights for internal medicine specialists and subspecialists outside of rheumatology. The first study investigated the effect of low-dose glucocorticoids on patients with rheumatoid arthritis (RA) over 2 years and challenged existing perceptions about the risks of glucocorticoids in this setting. The second study focused on the updated guideline for...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Kafaf Jalali Lisa A Mandl Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
